28. 全身性アミロイドーシス Systemic amyloidosis Clinical trials / Disease details


臨床試験数 : 267 薬物数 : 241 - (DrugBank : 77) / 標的遺伝子数 : 68 - 標的パスウェイ数 : 180

  
9 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04882735
(ClinicalTrials.gov)
September 202129/4/2021Efficacy and Safety of Acoramidis (AG10) in Subjects With Transthyretin Amyloid Polyneurophathy (ATTRibute-PN)A Phase 3, Open-Label, Multicenter, Single-Arm Study to Evaluate the Efficacy and Safety of Acoramidis in Subjects With Symptomatic Transthyretin Amyloid Polyneuropathy (ATTRibute-PN Study)Transthyretin-Related (ATTR) Familial Amyloid PolyneuropathyDrug: AcoramidisEidos TherapeuticsNULLNot yet recruiting18 Years90 YearsAll100Phase 3NULL
2EUCTR2018-004670-10-BG
(EUCTR)
25/11/202004/08/2020Study of the Efficacy and Safety of AG10 in participants with Transthyretin Amyloid Polyneuropathy (ATTR-PN)A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of AG10 in Subjects with Symptomatic Transthyretin Amyloid Polyneuropathy (ATTRibute-PN Trial) - Efficacy and Safety of AG10 in participants with Transthyretin Amyloid Polyneuropathy (ATTR-PN) Symptomatic Transthyretin Amyloid Polineuropathy (ATTR-PN)
MedDRA version: 20.0;Level: LLT;Classification code 10057949;Term: Familial amyloid polyneuropathy;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: AG10
Product Code: AG10 HCl
INN or Proposed INN: AG10 HCl
Other descriptive name: 3-(3-(3,5-DIMETHYL-1H-PYRAZOL-4-YL)PROPOXY)-4-FLUOROBENZOIC ACID
Eidos Therapeutics, Inc.NULLNot RecruitingFemale: yes
Male: yes
145Phase 3Portugal;Taiwan;Spain;Turkey;Russian Federation;Italy;France;Hungary;Mexico;Canada;Argentina;Brazil;Poland;Bulgaria;Germany;Netherlands;New Zealand
3NCT04418024
(ClinicalTrials.gov)
October 21, 202022/5/2020Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid PolyneurophathyA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of AG10 in Subjects With Symptomatic Transthyretin Amyloid Polyneuropathy (ATTRibute-PN Trial)Transthyretin-Related (ATTR) Familial Amyloid PolyneuropathyDrug: AG10;Drug: PlaceboEidos Therapeutics, a BridgeBio companyNULLWithdrawn18 Years90 YearsAll0Phase 3United States;Canada;Spain
4EUCTR2018-004670-10-FR
(EUCTR)
29/09/202005/06/2020Study of the Efficacy and Safety of AG10 in participants with Transthyretin Amyloid Polyneuropathy (ATTR-PN)A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of AG10 in Subjects with Symptomatic Transthyretin Amyloid Polyneuropathy (ATTRibute-PN Trial) - Efficacy and Safety of AG10 in participants with Transthyretin Amyloid Polyneuropathy (ATTR-PN) Symptomatic Transthyretin Amyloid Polineuropathy (ATTR-PN)
MedDRA version: 20.0;Level: LLT;Classification code 10057949;Term: Familial amyloid polyneuropathy;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: AG10
Product Code: AG10 HCl
INN or Proposed INN: AG10 HCl
Other descriptive name: 3-(3-(3,5-DIMETHYL-1H-PYRAZOL-4-YL)PROPOXY)-4-FLUOROBENZOIC ACID
Eidos Therapeutics, Inc.NULLNot RecruitingFemale: yes
Male: yes
145Phase 3Portugal;Taiwan;Spain;Turkey;Russian Federation;Italy;France;Hungary;Mexico;Canada;Argentina;Brazil;Poland;Bulgaria;Germany;Netherlands;New Zealand
5EUCTR2018-004670-10-DE
(EUCTR)
28/09/202025/05/2020Study of the Efficacy and Safety of AG10 in participants with Transthyretin Amyloid Polyneuropathy (ATTR-PN)A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of AG10 in Subjects with Symptomatic Transthyretin Amyloid Polyneuropathy (ATTRibute-PN Trial) - Efficacy and Safety of AG10 in participants with Transthyretin Amyloid Polyneuropathy (ATTR-PN) Symptomatic Transthyretin Amyloid Polineuropathy (ATTR-PN)
MedDRA version: 20.0;Level: LLT;Classification code 10057949;Term: Familial amyloid polyneuropathy;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: AG10
Product Code: AG10 HCl
INN or Proposed INN: AG10 HCl
Other descriptive name: 3-(3-(3,5-DIMETHYL-1H-PYRAZOL-4-YL)PROPOXY)-4-FLUOROBENZOIC ACID
Eidos Therapeutics, Inc.NULLNot RecruitingFemale: yes
Male: yes
145Phase 3Portugal;Taiwan;Spain;Turkey;Russian Federation;Italy;France;Hungary;Mexico;Canada;Argentina;Brazil;Poland;Bulgaria;Germany;Netherlands;New Zealand
6EUCTR2018-004670-10-PT
(EUCTR)
31/08/202004/06/2020Study of the Efficacy and Safety of AG10 in participants with Transthyretin Amyloid Polyneuropathy (ATTR-PN)A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of AG10 in Subjects with Symptomatic Transthyretin Amyloid Polyneuropathy (ATTRibute-PN Trial) - Efficacy and Safety of AG10 in participants with Transthyretin Amyloid Polyneuropathy (ATTR-PN) Symptomatic Transthyretin Amyloid Polineuropathy (ATTR-PN)
MedDRA version: 20.0;Level: LLT;Classification code 10057949;Term: Familial amyloid polyneuropathy;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: AG10
Product Code: AG10 HCl
INN or Proposed INN: AG10 HCl
Other descriptive name: 3-(3-(3,5-DIMETHYL-1H-PYRAZOL-4-YL)PROPOXY)-4-FLUOROBENZOIC ACID
Eidos Therapeutics, Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
145Phase 3Portugal;New Zealand;Taiwan;Turkey;Russian Federation;Spain;Italy;France;Hungary;Mexico;Canada;Argentina;Brazil;Poland;Bulgaria;Germany;Netherlands
7EUCTR2018-004670-10-IT
(EUCTR)
24/07/202024/05/2021Study of the Efficacy and Safety of AG10 in participants with Transthyretin Amyloid Polyneuropathy (ATTR-PN)A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of AG10 in Subjects with Symptomatic Transthyretin Amyloid Polyneuropathy (ATTRibute-PN Trial) - Efficacy and Safety of AG10 in participants with Transthyretin Amyloid Polyneuropathy (ATTR-PN) Symptomatic Transthyretin Amyloid Polineuropathy (ATTR-PN)
MedDRA version: 20.0;Level: LLT;Classification code 10057949;Term: Familial amyloid polyneuropathy;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: AG10
Product Code: [AG10 HCl]
INN or Proposed INN: AG10 HCl
Other descriptive name: 3-(3-(3,5-DIMETHYL-1H-PYRAZOL-4-YL)PROPOXY)-4-FLUOROBENZOIC ACID
Eidos Therapeutics, IncNULLNot RecruitingFemale: yes
Male: yes
145Phase 3Portugal;Taiwan;Spain;Turkey;Russian Federation;Italy;France;Hungary;Mexico;Canada;Argentina;Poland;Brazil;Bulgaria;Germany;Netherlands;New Zealand
8EUCTR2018-004670-10-HU
(EUCTR)
07/07/202012/05/2020Study of the Efficacy and Safety of AG10 in participants with Transthyretin Amyloid Polyneuropathy (ATTR-PN)A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of AG10 in Subjects with Symptomatic Transthyretin Amyloid Polyneuropathy (ATTRibute-PN Trial) - Efficacy and Safety of AG10 in participants with Transthyretin Amyloid Polyneuropathy (ATTR-PN) Symptomatic Transthyretin Amyloid Polineuropathy (ATTR-PN)
MedDRA version: 20.0;Level: LLT;Classification code 10057949;Term: Familial amyloid polyneuropathy;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: AG10
Product Code: AG10 HCl
INN or Proposed INN: AG10 HCl
Other descriptive name: 3-(3-(3,5-DIMETHYL-1H-PYRAZOL-4-YL)PROPOXY)-4-FLUOROBENZOIC ACID
Eidos Therapeutics, Inc.NULLNot RecruitingFemale: yes
Male: yes
145Phase 3Portugal;Taiwan;Spain;Turkey;Russian Federation;Italy;France;Hungary;Mexico;Canada;Argentina;Brazil;Poland;Bulgaria;Germany;Netherlands;New Zealand
9EUCTR2018-004670-10-NL
(EUCTR)
03/02/2021Study of the Efficacy and Safety of AG10 in participants with Transthyretin Amyloid Polyneuropathy (ATTR-PN)A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of AG10 in Subjects with Symptomatic Transthyretin Amyloid Polyneuropathy (ATTRibute-PN Trial) - Efficacy and Safety of AG10 in participants with Transthyretin Amyloid Polyneuropathy (ATTR-PN) Symptomatic Transthyretin Amyloid Polineuropathy (ATTR-PN)
MedDRA version: 20.0;Level: LLT;Classification code 10057949;Term: Familial amyloid polyneuropathy;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: AG10
Product Code: AG10 HCl
INN or Proposed INN: AG10 HCl
Other descriptive name: 3-(3-(3,5-DIMETHYL-1H-PYRAZOL-4-YL)PROPOXY)-4-FLUOROBENZOIC ACID
Eidos Therapeutics, Inc.NULLNot RecruitingFemale: yes
Male: yes
145Phase 3Portugal;Serbia;Taiwan;Spain;Turkey;Russian Federation;Italy;France;Hungary;Mexico;Canada;Argentina;Poland;Brazil;Bulgaria;Netherlands;Germany;New Zealand